Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11251 - 11275 of 12063 in total
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Experimental
Matched Description: … Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers …
Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).
Investigational
Matched Description: … Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial …
SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).
Investigational
Matched Description: … SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability …
Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).
Investigational
Matched Description: … Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ …
Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Investigational
Matched Description: … investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A
Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Investigational
Matched Description: … Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety …
CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).
Investigational
Matched Description: … CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and …
Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).
Investigational
Matched Description: … Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative …
GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
Investigational
Matched Description: … GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness …
LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.
Investigational
Matched Description: … LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy …
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Matched Description: … MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) …
MOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.
Investigational
Matched Description: … MOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus …
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
Matched Description: … ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a
The (R)-enantiomer of rolipram, it is a phosphodiesterase inhibitor with antidepressant properties.
Experimental
Matched Description: … The (R)-enantiomer of rolipram, it is a phosphodiesterase inhibitor with antidepressant properties. …
A guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem]
Experimental
Matched Description: … A guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem] …
A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.
Experimental
Matched Description: … A non-steroidal anti-inflammatory drug approved for use in Japan in 1993. …
Landiolol is a rapid-acting beta-blocker used for rapid ventricular rate control.
Investigational
Matched Description: … Landiolol is a rapid-acting beta-blocker used for rapid ventricular rate control. …
KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
Investigational
Matched Description: … KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical. …
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
Matched Description: … TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide. …
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Matched Description: … LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9. …
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
Matched Description: … HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
XTMAB-16 is a monoclonal antibody directed against tumour necrosis factor-alpha (TNFα).
Investigational
Matched Description: … XTMAB-16 is a monoclonal antibody directed against tumour necrosis factor-alpha (TNFα). …
Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. Putrescine is a solid. This compound belongs to the polyamines. These are compounds containing more than one amine group. Known drug targets of putrescine include putrescine-binding periplasmic protein, ornithine decarboxylase, and S-adenosylmethionine decarboxylase proenzyme.
Experimental
Matched Description: … Putrescine is a solid. This compound belongs to the polyamines. ... Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine …
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable …
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Investigational
Matched Description: … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves ... Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical …
Displaying drugs 11251 - 11275 of 12063 in total